Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial.
Sonja B VliekIris NoordhoekElma Meershoek-Klein KranenbargAnnelot G J van RossumVincent O DezentjeAgnes JagerJ W Esmeralda HokkenHein PutterAnnette W G van der VeldenMarieke H J van den Beuken-van EverdingenSandra D BakkerYvonne E A van RietVivianne C G Tjan-HeijnenJohanneke E A PortieljeJudith R KroepJohan W R NortierCornelis J H van de VeldeSabine C LinnPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
In postmenopausal women with ER+ breast cancer, adjuvant ibandronate 50 mg once daily does not improve DFS and should not be recommended as part of standard treatment regimens.
Keyphrases
- phase iii
- estrogen receptor
- positive breast cancer
- open label
- clinical trial
- double blind
- phase ii
- placebo controlled
- early stage
- bone mineral density
- physical activity
- breast cancer risk
- palliative care
- randomized controlled trial
- postmenopausal women
- combination therapy
- quality improvement
- young adults
- replacement therapy
- endoplasmic reticulum